熱門資訊> 正文
Ocugen获得FDA批准开始OCU410ST的中期研究
2025-06-16 21:38
- Ocugen (NASDAQ:OCGN) said on Monday that the U.S. FDA has cleared the company to initiate a phase 2/3 confirmatory trial of its modifier gene therapy, OCU410ST, to treat Stargardt disease, an eye disorder.
- The FDA has already designated OCU410ST as a Rare Pediatric Disease and an Orphan Drug for treating specific retinal disorders linked to the ABCA4 gene, such as Stargardt disease and others.
- Ocugen intends to file a marketing application for OCU410ST in 2027.
- Stock is up 12.4% today.
More on Ocugen
- Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
- Ocugen signs license deal with Korean company for gene therapy
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Seeking Alpha’s Quant Rating on Ocugen
- Historical earnings data for Ocugen
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
